Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) will be releasing its earnings data after the market closes on Monday, November 20th. Analysts expect Enanta Pharmaceuticals to post earnings of $1.88 per share for the quarter.
Enanta Pharmaceuticals, Inc. (ENTA) opened at $47.97 on Monday. Enanta Pharmaceuticals, Inc. has a fifty-two week low of $25.92 and a fifty-two week high of $50.92.
Several equities research analysts have commented on ENTA shares. Royal Bank Of Canada started coverage on shares of Enanta Pharmaceuticals in a report on Thursday, September 14th. They set an “outperform” rating on the stock. JMP Securities upped their price objective on shares of Enanta Pharmaceuticals from $40.00 to $53.00 in a report on Wednesday, October 4th. Zacks Investment Research downgraded shares of Enanta Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Wednesday, October 4th. J P Morgan Chase & Co reaffirmed an “overweight” rating and set a $38.00 price objective (up from $32.00) on shares of Enanta Pharmaceuticals in a report on Wednesday, August 9th. Finally, BidaskClub raised shares of Enanta Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Friday, August 11th. Three research analysts have rated the stock with a hold rating and four have given a buy rating to the company. The company has an average rating of “Buy” and a consensus target price of $45.25.
About Enanta Pharmaceuticals
Enanta Pharmaceuticals, Inc is a research and development-focused biotechnology company. The Company uses chemistry-driven approach and drug discovery solutions to create small molecule drugs for the treatment of viral infections and liver diseases. Its research and development programs are focused on three disease targets: non-alcoholic steatohepatitis (NASH)/ primary biliary cholangitis (PBC), respiratory syncytial virus (RSV) and hepatitis B virus (HBV).
Receive News & Ratings for Enanta Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enanta Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.